Zimmer BiometZBHEarnings & Financial Report
Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
ZBH Q3 2025 Key Financial Metrics
Revenue
$2.0B
Gross Profit
$1.4B
Operating Profit
$351.3M
Net Profit
$230.9M
Gross Margin
72.1%
Operating Margin
17.6%
Net Margin
11.5%
YoY Growth
9.7%
EPS
$1.16
Financial Flow
Zimmer Biomet Q3 2025 Financial Summary
Zimmer Biomet reported revenue of $2.0B for Q3 2025, with a net profit of $230.9M (11.5% margin). Cost of goods sold was $559.3M, operating expenses totaled $1.1B.
Key Financial Metrics
| Total Revenue | $2.0B |
|---|---|
| Net Profit | $230.9M |
| Gross Margin | 72.1% |
| Operating Margin | 17.6% |
| Report Period | Q3 2025 |
Zimmer Biomet Annual Revenue by Year
Zimmer Biomet annual revenue history includes year-by-year totals (for example, 2024 revenue was $7.7B).
| Year | Annual Revenue |
|---|---|
| 2024 | $7.7B |
| 2023 | $7.4B |
| 2022 | $6.9B |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.94B | $1.89B | $1.94B | $1.82B | $2.02B | $1.91B | $2.08B | $2.00B |
| YoY Growth | 6.3% | 3.2% | 3.9% | 4.0% | 4.3% | 1.1% | 7.0% | 9.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $21.50B | $21.45B | $21.52B | $21.72B | $21.37B | $22.18B | $22.87B | $23.49B |
| Liabilities | $9.01B | $8.85B | $8.77B | $9.34B | $8.89B | $9.78B | $10.33B | $10.72B |
| Equity | $12.48B | $12.60B | $12.74B | $12.37B | $12.47B | $12.40B | $12.53B | $12.76B |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $588.4M | $228.0M | $369.4M | $395.7M | $506.3M | $382.8M | $378.2M | $418.7M |
Other Health Care Companies
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
BAX
Baxter International
Revenue
$3.0B
Net Profit
$-1.1B
BDX
Becton Dickinson
Revenue
$5.3B
Net Profit
$382.0M
BSX
Boston Scientific
Revenue
$5.3B
Net Profit
$670.0M
DXCM
Dexcom
Revenue
$1.3B
Net Profit
$267.3M
EW
Edwards Lifesciences
Revenue
$1.6B
Net Profit
$291.1M
GEHC
GE HealthCare
Revenue
$5.7B
Net Profit
$588.0M
HOLX
Hologic
Revenue
$1.0B
Net Profit
$179.1M
IDXX
Idexx Laboratories
Revenue
$1.1B
Net Profit
$274.6M
PODD
Insulet Corporation
Revenue
$783.7M
Net Profit
$101.6M